Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farrah Pompilus

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 26, 2018
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric studySophie Cleanthous, Sara Strzok, Farrah Pompilus, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 10, 2018
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods studySara Strzok, Sophie Cleanthous, Farrah Pompilus, et al.
Health and Quality of Life Outcomes|April 13, 2019
Development of a symptom assessment in patients with myelofibrosis: qualitative study findingsRuben A Mesa, Yun Su, Adrien Woolfson, et al.
Neurosurgical Review|March 14, 2020
Minimally invasive versus open surgery for the correction of adult degenerative scoliosis: a systematic reviewAsad M Lak, Nayan Lamba, Farrah Pompilus, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 26, 2018
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric studySophie Cleanthous, Sara Strzok, Farrah Pompilus, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 10, 2018
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods studySara Strzok, Sophie Cleanthous, Farrah Pompilus, et al.
Health and Quality of Life Outcomes|April 13, 2019
Development of a symptom assessment in patients with myelofibrosis: qualitative study findingsRuben A Mesa, Yun Su, Adrien Woolfson, et al.
Neurosurgical Review|March 14, 2020
Minimally invasive versus open surgery for the correction of adult degenerative scoliosis: a systematic reviewAsad M Lak, Nayan Lamba, Farrah Pompilus, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
Pageof 2